When multiple metastatic lesions are detected in the head and neck region, CyberKnife technology enables precise, simultaneous targeting — offering patients a highly efficient and minimally invasive treatment option.

Head and neck metastases often originate from cancers such as lung, breast, or prostate cancer. Treatment is particularly challenging due to the region’s complex anatomy, dense network of nerves and blood vessels, and its vital roles in breathing, swallowing, and speech.

Traditional radiotherapy techniques struggle to address multiple scattered lesions simultaneously, while surgical removal is typically unsuitable for diffuse metastases. As an advanced stereotactic radiosurgery (SRS) system, CyberKnife provides a new approach to treating multifocal head and neck metastases.

1. Clinical Features and Diagnostic Challenges

Head and neck metastases are relatively common among cancer patients, occurring in approximately 15–30% of cases. Lung cancer is the most frequent primary source, followed by breast, gastrointestinal, genitourinary cancers, and malignant melanoma.

These metastases are most common among patients aged 40–60 and may appear in various head and neck structures, including the skull base, mandible, and cervical lymph nodes. Depending on distribution, they can be classified as solitary, multiple, or diffuse.

Head and neck metastases typically progress rapidly, often accompanied by early and severe tissue reactions. Patients may experience localized pain, neurological dysfunction (such as facial numbness or hoarseness), difficulty swallowing, or palpable lumps. Without treatment, the average survival time is only 1–3 months.

2. Challenges in Traditional Treatment of Multifocal Metastases

Treating multifocal metastases in the head and neck presents several challenges:

Limitations of surgery: Multiple scattered lesions cannot be removed in a single operation, and repeated surgeries increase trauma and risk, often compromising critical functions. Deep-seated lesions pose additional surgical difficulty.

Drawbacks of conventional radiotherapy: Traditional radiation covers large areas with limited precision. While destroying cancer cells, it also damages surrounding healthy tissues. When multiple lesions are irradiated simultaneously, cumulative exposure may cause severe side effects such as salivary gland dysfunction or soft-tissue fibrosis.

Constraints of chemotherapy: The blood–brain barrier limits drug penetration into certain areas of the head and neck, reducing effectiveness. Systemic chemotherapy also carries significant side effects and may not be tolerated by frail patients.

Difficulty in combination therapy: Multifocal metastases often require multimodal treatment. However, determining the proper sequence and timing is complex — improper coordination may increase toxicity or lead to overtreatment.

3. The Technology Behind CyberKnife Synchronous Therapy

CyberKnife is a robotic stereotactic radiosurgery system that delivers high-precision radiation without incisions or anesthesia. Unlike a traditional scalpel, it uses focused radiation beams to ablate tumors painlessly and noninvasively.

Real-time motion tracking: For head and neck tumors affected by physiological movement (e.g., swallowing or pulse), CyberKnife continuously tracks the tumor's motion and dynamically adjusts the beam path. This “target-tracking” precision reaches submillimeter accuracy (as fine as 0.1 mm).

Noninvasive and comfortable: CyberKnife treatment is painless and requires no hospitalization. Most patients complete treatment in 1–5 sessions, each lasting about 15–30 minutes, and can resume normal activities immediately afterward.

4. Clinical Applications in Multifocal Metastases

CyberKnife has shown remarkable efficacy in treating multifocal metastases in the head and neck region, including:

Synchronous treatment of multiple brain metastases: CyberKnife can simultaneously target numerous intracranial lesions. Clinical studies report local tumor control rates exceeding 90%, with median survival extended to 10–14 months. Even patients with more than 20 brain metastases have achieved excellent results, with improved symptoms and long-term disease stabilization.

Lesions in complex skull base and head–neck regions: CyberKnife excels in treating metastases located in anatomically challenging areas such as the skull base, orbit, and nasopharynx — regions where surgery and conventional radiotherapy carry high risks. Its ability to “sculpt” the radiation dose allows precise tumor targeting while sparing critical nerves and vessels.

Postoperative or recurrent metastases: For patients with recurrence after surgery or radiotherapy, CyberKnife offers an effective salvage option. It accurately targets recurrent sites without re-irradiating previously high-dose areas.

Coordinated treatment of systemic metastases: Beyond the head and neck, CyberKnife can also treat metastatic lesions in the lungs, liver, bones, and other organs, enabling integrated management of systemic metastases through simultaneous or sequential therapy.

5. CyberKnife vs. Conventional Radiotherapy: A Comparative Advantage

For multifocal head and neck metastases, CyberKnife demonstrates distinct advantages over traditional radiotherapy:

Superior precision: CyberKnife's targeting error is less than 1 mm — far beyond conventional systems. This submillimeter accuracy is vital for treating the intricate head and neck anatomy.

Shorter treatment duration: Conventional whole-brain radiotherapy typically requires 25–30 sessions over 4–6 weeks. In contrast, CyberKnife achieves comparable or better results in just 1–5 sessions, usually within a week — greatly reducing patient burden.

Fewer side effects: Focused dose delivery reduces exposure to surrounding healthy tissue by over 50%, minimizing radiation-induced damage and preserving vital functions such as salivation and swallowing.

Repeatable treatment: Because CyberKnife causes minimal harm to normal tissue, it can safely be repeated for new or recurrent metastases, supporting long-term disease control.

Enhanced overall efficacy: With its shorter course and lower toxicity, CyberKnife allows patients to tolerate subsequent systemic therapies (e.g., chemotherapy, targeted therapy) more effectively, achieving an optimal balance between local and systemic control.

6. Specialized Application at Foshan Chancheng Hospital

At Foshan Chancheng Hospital, the CyberKnife Center has developed distinctive expertise in treating multifocal head and neck metastases:

Cutting-edge equipment: The hospital is equipped with the sixth-generation CyberKnife M6, one of the most advanced radiosurgery systems available. With submillimeter precision and intelligent real-time tracking, it provides the technological foundation for accurate multifocal treatment.

Personalized treatment planning: Each patient receives an individualized plan, covering every stage from screening and diagnosis to therapy and recovery. Comprehensive management addresses not only physical but also psychological well-being through a multidisciplinary approach.

Multidisciplinary collaboration (MDT): The center brings together experts from radiation oncology, imaging, neurosurgery, and head and neck surgery to design the most suitable and evidence-based treatment strategy for each patient.

For patients with multifocal head and neck metastases, CyberKnife offers an efficient, precise, and minimally invasive alternative — particularly for those who are inoperable or unresponsive to conventional therapy. With continued advancements in radiotherapy technology, the application of CyberKnife in metastatic head and neck cancer is expected to expand, offering renewed hope for patients facing complex disease patterns.